Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III ...

A review of recent trends and remaining challenges in bispecific antibody (bsAb) production has been published.

Novo Nordisk has bolstered the case for its near-approval hemophilia A drug candidate Mim8, linking the prospect to ...

Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked ...

Zenocutuzumab is a novel bispecific antibody designed by Merus, N.V. In a multicenter global phase 2 clinical trial led by MSK gynecologic medical oncologist and early drug development specialist ...

The layoffs follow an announcement in early January that I-Mab will re-prioritize resources to focus on advancing a CLDN18.2 ...

Recombinant antibodies are invented antibodies formed by using recombinant DNA technology. While traditional monoclonal ...

Orion Corp. and Invenra Inc. have entered into a research collaboration to discover bispecific antibodies using Invenra’s B-Body platform.

Jeffrey V. Matous, MD, discusses how primary barriers to the widespread use of bispecific antibody therapies in community ...

ORION CORPORATION PRESS RELEASE 30 JANUARY 2025 at 16.00 EET Orion and Invenra announce discovery service and commercial ...

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

Jeffrey V. Matous, MD, discusses how telehealth and remote monitoring can enhance the safe administration of bispecific ...